Coexistence of JAK2V617F Mutation and BCR–ABL Translocation in a Pregnant Woman with Essential Thrombocythemia

Caocci G, Atzeni S, Orrù N et al (2010) Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR–ABL oncoprotein and JAK2V617F mutation. Leuk Res 34(1):e27–e29

Hussein K, Bock O, Seegers A et al (2007) Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR–ABL translocation and JAK2V617F mutation. Blood 109(9):4106–4107

Toogeh G, Ferdowsi S, Naadali F et al (2011) Concomitant presence of JAK2 V617F mutation and BCR–ABL translocation in a pregnant woman with polycythemia vera. Med Oncol 28(4):1555–1558

Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061

Cappetta M, Pérez V, Zubillaga MN et al (2013) Concomitant detection of BCR–ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol 35(1):e4–e5

Conchon MR, Costa JL, Novaes MM et al (2008) Simultaneous detection of JAK2 V617F mutation and Bcr–Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 88(2):243–245

Hussein K, Bock O, Theophile K et al (2008) Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation. Leukemia 22(5):1059–1062

Bornhäuser M, Mohr B, Oelschlaegel U et al (2007) Concurrent JAK2(V617F) mutation and BCR–ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21(8):1824–1826

Mirza I, Frantz C, Clarke G et al (2007) Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 131(11):1719–1724

Bocchia M, Vannucchi AM, Gozzetti A et al (2007) Insights into JAK2-V617F mutation in CML. Lancet Oncol 8(10):864–866

Hummel JM, Kletecka MC, Sanks JK et al (2012) Concomitant BCR–ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol 21(3):176–183

Krämer A, Reiter A, Kruth J et al (2007) JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8(7):658–660

Pardini S, Fozza C, Contini S et al (2008) A case of coexistence between JAK2V617F and BCR/ABL. Eur J Haematol 81(1):75–76

Pieri L, Spolverini A, Scappini B et al (2011) Concomitant occurrence of BCR–ABL and JAK2V617F mutation. Blood 118(12):3445–3446

Pingali SR, Mathiason MA, Lovrich SD et al (2009) Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: jAK2V617F as a potential risk factor for BCR–ABL translocation. Clin Lymphoma Myeloma 9(5):E25–E29

Tefferi A, Levitt R, Lasho TL et al (2010) Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol 85(1):86–87

Krämer A (2008) JAK2-V617F and BCR–ABL–double jeopardy? Leuk Res 32(10):1489–1490

Gattenlohner S, Völker HU, Etschmann B et al (2009) BCR–ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol 84(5):306–307

Bee PC, Gan GG, Nadarajan VS et al (2010) A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 91(1):136–139

Véronèse L, Tchirkov A, Richard-Pebrel C et al (2010) A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. Leuk Res 34(4):e94–e96

Cambier N, Renneville A, Cazaentre T et al (2008) JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22(7):1454–1455

Campiotti L, Appio L, Solbiati F et al (2009) JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 33(11):e212–e213

Inokuchi K, Yamaguchi H, Tamai H et al (2012) Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia. J Clin Exp Hematop 52(2):145–147

Inami M, Inokuchi K, Okabe M et al (2007) Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21(5):1103–1104

Kim YK, Shin MG, Kim HR et al (2008) Simultaneous occurrence of the JAK2V617F mutation and BCR–ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res 32(6):993–995